GraniteShares Autocallable SMCI ETF logo

GraniteShares Autocallable SMCI ETF (SCA)

Market Open
12 Aug, 16:25
NYSE NYSE
$
23. 77
+0.85
+3.694%
$
914.95K Market Cap
- Div Yield
1 Volume
$ 22.92
Previous Close
Add Transaction
Day Range
22.11 24.02
Year Range
18.08 26.81
Want to track SCA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SCA trading today higher at $23.77, an increase of 3.694% from yesterday's close, completing a monthly increase of 16.724% or $3.41. Over the past 12 months, SCA stock lost -4.94%.
SCA pays dividends to its shareholders, with the most recent payment made on Jul 06, 2026. The next estimated payment will be in 6 days ago on Aug 06, 2026 for a total of $0.82945.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NYSE (USD).

SCA Chart

Svenska Cellulosa Aktiebolaget SCA (publ) (SCABY) Q2 2026 Earnings Call Transcript

Svenska Cellulosa Aktiebolaget SCA (publ) (SCABY) Q2 2026 Earnings Call Transcript

Svenska Cellulosa Aktiebolaget SCA (publ) (SCABY) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 weeks ago
Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials.

Seekingalpha | 1 year ago
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the phase 3 study using troriluzole for patients with spinocerebellar ataxia, an NDA submission is planned for Q4 of 2024. Troriluzole is also being explored for patients with obsessive compulsive disorder in two phase 3 studies; Data from these studies are expected before the end of 2024 and the 1st half of 2025.

Seekingalpha | 1 year ago

GraniteShares Autocallable SMCI ETF (SCA) FAQ

What is the stock price today?

The current price is $23.77.

On which exchange is it traded?

GraniteShares Autocallable SMCI ETF is listed on NYSE.

What is its stock symbol?

The ticker symbol is SCA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 914.95K.

Has GraniteShares Autocallable SMCI ETF ever had a stock split?

No, there has never been a stock split.

GraniteShares Autocallable SMCI ETF Profile

NYSE Exchange
US Country
This fund will allocate a significant portion—a minimum of 80%—of its total investable capital (which includes its net assets and any borrowed funds used for investment) to derivative instruments. The value and performance of these derivatives are specifically tied to an autocallable security, which in turn references an underlying asset. Importantly, the fund operates as a non-diversified investment vehicle.

Contact Information

Address: 205 Hudson Street, 7th Floor
Phone: -